Lubricin-inspired Osteoarthritis Treatment: a Unique Solution
NCT: NCT07611708 · NOT_YET_RECRUITING
Brief Summary
This goal of this open label study is to evaluate the safety and tolerability of a single intra-articular administration of ABR1 in adults with knee osteoarthritis with a KL grade from 2 to 4. The primary questions it aims to answer are: 1. Is ABR1 safe to use as an intraarticular injection for participants with knee osteoarthritis? 2. What medical problems do participants have after receiving a single injection of ABR1? Participants will receive a single injection of ABR1 to the knee with osteoarthritis. Participants will 1. Keep a stable pain treatment regimen 2. Visit the clinic at 1 week, 4 weeks, 8 weeks, and 12 weeks post injection 3. Keep a diary of their symptoms and number of times they use a rescue medication for their knee pain.
Frequently Asked Questions
What is Lubricin-inspired Osteoarthritis Treatment: a Unique Solution?
Lubricin-inspired Osteoarthritis Treatment: a Unique Solution is a clinical trial registered under NCT07611708. Current status: NOT_YET_RECRUITING.
What is the status of NCT07611708?
The current status of NCT07611708 (Lubricin-inspired Osteoarthritis Treatment: a Unique Solution) is: NOT_YET_RECRUITING.
When did Lubricin-inspired Osteoarthritis Treatment: a Unique Solution start?
Lubricin-inspired Osteoarthritis Treatment: a Unique Solution started on 2026-08.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.